It's nice to see the Selecta Biosciences, Inc. (NASDAQ:SELB) share price up 22% in a week. But will that repair the damage for the weary investors who have owned this stock as it declined over half a ...
Selecta Biosciences is a biotech firm working on therapies for rare illnesses. SEL-212, its lead product, helps control uric acid levels in chronic refractory gout patients. SEL-212 controls serum ...
· Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta's breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need ...
Seven years. One unforgettable night. This November, Selecta celebrates 7 incredible years by returning to where it all began. The Ark in Newmarket is where the Selecta journey first started, and for ...
WATERTOWN, Mass. and STOCKHOLM, Sweden, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline ...
Selecta Biosciences Inc SELB provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the ...
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results